G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 25 PLN -1.57% Market Closed
Market Cap: 33m PLN
Have any thoughts about
Genomed SA?
Write Note

Gross Margin
Genomed SA

44%
Current
39%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
44%
=
Gross Profit
9.7m
/
Revenue
22.1m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
PL
Genomed SA
WSE:GEN
33m PLN
44%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
314.9B USD
67%
US
Amgen Inc
NASDAQ:AMGN
140.6B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.9B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.8B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country PL
Market Cap 33m PLN
Gross Margin
44%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 314.9B USD
Gross Margin
67%
Country US
Market Cap 140.6B USD
Gross Margin
60%
Country US
Market Cap 115.7B USD
Gross Margin
78%
Country US
Market Cap 103.9B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 77.8B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Genomed SA
Glance View

Market Cap
33m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Undervaluation 1%
Intrinsic Value
Price
G

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
44%
=
Gross Profit
9.7m
/
Revenue
22.1m
What is the Gross Margin of Genomed SA?

Based on Genomed SA's most recent financial statements, the company has Gross Margin of 44%.